Science AI Journal
Medicine · Research topic

Open research questions in Cytomegalovirus and herpesvirus research

25 unresolved questions extracted from the limitations and future-work sections of 251 Cytomegalovirus and herpesvirus research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Prospective cohort studies that measure these markers before and during pregnancy, ideally with serial sampling, are needed to clarify temporal relationships and any predictive value for live birth. CMV status should be characterised more completely using IgG avidity and quantitative PCR to separate latent from active or reactivated infection. External, multi-centre validation in independent Iraqi and international populations is essential before any cut-off is adopted, and mechanistic studies of decidual and trophoblast tissue could test whether the serum changes reflect events at the maternal–fetal interface. Finally, interventional work could explore whether modulating the HMGB1/PTX-3 axis or restoring tolerogenic signalling affects outcomes in carefully selected women.

    SERUM IL-35, PENTRAXIN-3, GALECTIN-3 AND HMGB1 IN RECURRENT PREGNANCY LOSS STRATIFIED BY CYTOMEGALOVIRUS SEROSTATUS: A CASE–CONTROL STUDY OF IRAQI WOMEN · 2026 · DOI

  • The pooled prevalence of approximately 3% indicates that cytomegalovirus retinitis remains a clinically significant and under-recognized opportunistic infection, affecting nearly one in thirty individuals with advanced immunosuppression.

    Prevalence and Risk Factors for Cytomegalovirus Retinitis Among People Living with HIV in Sub-Saharan Africa in the Antiretroviral Therapy Era: A Systematic Review and Meta-Analysis · 2026 · DOI

  • Although no standardized diagnostic criteria exist, the lymphocyte and histiocyte infiltration with tissue necrosis in this case sug- gests CNS involvement in HPS based on the exclusion of other possible diseases (25). These findings are inconsistent with those of the present case.

    Autopsy Case of a Disseminated Cytomegalovirus Infection with a Cutaneous Ulcer Mimicking Rheumatoid Vasculitis · 2026 · DOI

  • Introduction In immunocompetent individuals, past CMV infection has been linked to venous thromboembolism (VTE) risk, but evidence remains inconclusive due to timing of serologic diagnosis.

    The risk of venous thromboembolism in kidney transplant recipients is enhanced following a cytomegalovirus infection · 2026 · DOI

  • Due to its recent availability, real-world data on letermovir prophylactic use are scarce, with recent studies advocating for an extension of its duration from 100 to 200 days.

    Real-world use of letermovir for CMV prevention in allogeneic hematopoietic cell transplantation recipients in France: a national claims database study · 2026 · DOI

  • Abstract Background The optimal dosing strategy for valganciclovir (VGCV) prophylaxis against cytomegalovirus (CMV) infection in pediatric patients after kidney transplantation (KT) remains uncertain because of the narrow therapeutic window between antiviral efficacy and safety.

    Efficacy and safety of reduced-dose valganciclovir prophylaxis for cytomegalovirus infection after pediatric kidney transplantation · 2026 · DOI

  • InterpretationThe observed correlation between salivary HHV-6 shedding and symptom severity suggests HHV-6 may contribute to post-acute disease, though mechanisms remain unclear.

    Analysis Of Salivary Herpesviruses Reveals Associations Between HHV-6 And Long COVID Severity · 2026 · DOI

  • The main limitation is the relatively small number of treated cases, reflecting the recent introduction of valacy- clovir into clinical practice and the strict inclusion criteria. Retrospective design and heterogeneity of imaging plat- forms represent additional constraints. Nevertheless, the statistically significant findings despite limited numbers strengthen the clinical relevance of the observed trends. Another limitation of the present study is that, within the group of treated patients, the fetal MRI examinations were performed using different scanners (1.5 T vs 3 T) and at two separate imaging centers. Although standar- dized protocols were applied, differences in field strength, coil type, and scanner performance may have affected image quality and the detection of subtle brain abnorm- alities. This variability represents an additional limitation, as it could have influenced the assessment of minor lesions and their apparent progression over time. Fur- thermore, the difference in the range of MRI acquisition dates between the treated and untreated groups, linked to the more recent availability of in utero therapy, also represents a limitation, as it may introduce potential temporal bias in imaging and case selection.

    Serial prenatal MRI evaluation of valacyclovir-treated vs untreated fetuses with congenital cytomegalovirus (cCMV) infection · 2026 · DOI

  • Future research should focus on multicenter, prospective trials to further clarify the role of valacyclovir in con- genital CMV infection. Such studies are needed to con- firm the protective effect of the therapy on MRI outcomes, to better understand the relationship between dosage and treatment duration, and to determine the optimal therapeutic regimen. Additionally, it will be important to correlate imaging findings with long-term clinical outcomes, including both audiological and neurocognitive development, in order to establish the clinical relevance of observed brain changes. Finally, identifying reliable biomarkers—such as viral load immunological markers—may help measurements or predict the evolution of brain lesions and guide indivi- dualized treatment strategies.

    Serial prenatal MRI evaluation of valacyclovir-treated vs untreated fetuses with congenital cytomegalovirus (cCMV) infection · 2026 · DOI

  • While real-world data can provide valuable insights to complement traditional experimental data, any interpretations should consider all associated limitations, such as the impact of unmeasured, confounding, and missing data.28,29 This study reported the burden of neutropenia and/or leukopenia in KTRs who received valganciclovir; however, this study did not include a comparator group of KTRs who did not receive valganciclovir, and therefore the direct association between valganciclovir and neutropenia or leukopenia was not assessed. Neutropenia and leukopenia have several etiologies in KTRs, and the neutropenia/leukopenia in patients included in this analysis may not be the result of valganciclovir. Further analysis would be needed to explore this association. This study aimed to quantify all-cause utilization and costs, accounting for patient characteristics, rather than limiting analysis to kidney transplant-related outcomes only. While the HCRU and costs presented here may not be associated with kidney transplant and related sequelae, considering the variation in coding practices across the US, the methodology applied here provided a comprehensive approach to capture the costs of care that may have been induced or exacerbated by kidney transplant. Moreover, clinical outcomes of interest included CMV and other viral, fungal and bacterial infections, which may not have been captured with kidney transplant as the primary diagnosis code, therefore considering all-cause costs rather than kidney-transplant-related costs allowed for analysis of these outcomes. The Merative™ MarketScan® database covers individuals insured through large US employers, as well as those with supplemental Medicare coverage; therefore, the study population may not truly reflect the real-world US kidney transplant population, where the most frequent Turzhitsky V, et al.JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH 166 age bracket is >50 years.30 While the observed reduction in transplant procedures in recent years observed in this study may be explained by Merative™ MarketScan® having a reduced population pool over time,30 further studies are required to fully characterize the rate of kidney transplant and burden of CMV-related complications in the US population over 50 years of age. Further, CMV serostatus information is not available through the Merative™ MarketScan® database. To address this, the study sample was restricted to those receiving valganciclovir, as valganciclovir is only indicated for high-risk populations (D+/R−) in the US.5 However, current guidelines recommend valganciclovir use among patients with intermediate risk (R+)9; therefore, the study population could include a mixed population of patients with high or intermediate risk.

    Short and Long-Term Outcomes in Kidney Transplant Recipients with Neutropenia or Leukopenia Following CMV Prophylaxis · 2026 · DOI

  • Pathophysiology of deafness caused by cytomegalovirus infection is not well known, the mechanisms possible involved being impaired endolymphatic structures, cytopathic effect of the virus and the host response to the inner ear structures.

    Cytomegalovirus congenital infection – cause of neurosensorial hearing loss · 2016 · DOI

  • However, the exact incidence of symptomatic congenital CMV infection among children born to women with preexisting immunity remains to be defined.

    Symptomatic Congenital Cytomegalovirus Infection in Infants Born to Mothers With Preexisting Immunity to Cytomegalovirus · 1999 · DOI

  • It is not yet known whether otherwise healthy persons carrying such latent infection suffer recurrent reactivations, such as occur with herpes simplex, though such reactivations could obviously play an important part in the spread of infection.

    Prospective Study of Cytomegalovirus Infection in Pregnancy · 1973 · DOI

Most-cited papers in Cytomegalovirus and herpesvirus research

Most recent work

Find a gap in your own Cytomegalovirus and herpesvirus research sub-topic

This page shows what the Cytomegalovirus and herpesvirus research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
25 open questions have been extracted from the limitations and future-work passages of 251 Cytomegalovirus and herpesvirus research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.